Xiaoyan Yan
University at Buffalo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xiaoyan Yan.
American Journal of Physiology-heart and Circulatory Physiology | 2011
Alex Morrison; Xiaoyan Yan; Chao Tong; Ji Li
Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been demonstrated to possess cardioprotective properties during ischemia-reperfusion. However, this notion remains controversial as recent evidence has suggested an increased risk in cardiac events associated with long-term use of RGZ in patients with type 2 diabetes. In this study, we tested the hypothesis that acute RGZ treatment is beneficial during I/R by modulating cardioprotective signaling pathways in a nondiabetic mouse model. RGZ (1 μg/g) was injected intravenously via the tail vein 5 min before reperfusion. Myocardial infarction was significantly reduced in mice treated with RGZ compared with vehicle controls (8.7% ± 1.1% vs. 20.2% ± 2.5%, P < 0.05). Moreover, isolated hearts were subjected to 20 min of global, no-flow ischemia in an ex vivo heart perfusion system. Postischemic recovery was significantly improved with RGZ treatment administered at the onset of reperfusion compared with vehicle (P < 0.001). Immunoblot analysis data revealed that the levels of both phospho-AMP-activated protein kinase (Thr(172)) and phospho-Akt (Ser(473)) were significantly upregulated when RGZ was administered 5 min before reperfusion compared with vehicle. On the other hand, inflammatory signaling [phospho-JNK (Thr(183)/Tyr(185))] was significantly downregulated as a result of RGZ treatment compared with vehicle (P < 0.05). Intriguingly, pretreatment with the selective PPAR-γ inhibitor GW-9662 (1 μg/g iv) 10 min before reperfusion significantly attenuated these beneficial effects of RGZ on the ischemic heart. Taken together, acute treatment with RGZ can reduce ischemic injury in a nondiabetic mouse heart via modulation of AMP-activated protein kinase, Akt, and JNK signaling pathways, which is dependent on PPAR-γ activation.
Circulation | 2013
Jingying Wang; Chao Tong; Xiaoyan Yan; Eddie Yeung; Sunilkumar Gandavadi; Alissa A. Hare; Xin Du; Yibang Chen; Huabao Xiong; Changxing Ma; Lin Leng; Lawrence H. Young; William L. Jorgensen; Ji Li; Richard Bucala
Background Macrophage migration inhibitory factor (MIF) exerts a protective effect on ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules that increase the affinity of MIF for its receptor have been recently designed, and we hypothesized that such agonists may enhance AMPK activation and limit ischemic tissue injury.Background— Macrophage migration inhibitory factor (MIF) exerts a protective effect on ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules that increase the affinity of MIF for its receptor have been recently designed, and we hypothesized that such agonists may enhance AMPK activation and limit ischemic tissue injury. Methods and Results— Treatment of cardiomyocytes with the candidate MIF agonist, MIF20, augmented AMPK phosphorylation, increased by 50% the surface localization of glucose transporter, and enhanced by 25% cellular glucose uptake in comparison with MIF alone. In mouse hearts perfused with MIF20 before no-flow ischemia and reperfusion, postischemic left ventricular function improved commensurately with an increase in cardiac MIF-AMPK activation and an augmentation in myocardial glucose uptake. By contrast, small-molecule MIF agonism was not effective in cells or tissues genetically deficient in MIF or the MIF receptor, verifying the specificity of MIF20 for MIF-dependent AMPK signaling. The protective effect of MIF20 also was evident in an in vivo regional ischemia model. Mice treated with MIF20 followed by left coronary artery occlusion and reperfusion showed a significant reduction in infarcted myocardium. Conclusions— These data support the pharmacological utility of small-molecule MIF agonists in enhancing AMPK activation and reducing cardiac ischemic injury.
Toxicology Letters | 2011
Xiaoyan Yan; Xiaoting Yan; Alex Morrison; Tianlong Han; Qinglin Chen; Ji Li; Jundong Wang
In this study we investigated apoptosis and expression of the collagen I gene in newborn rat osteoblasts (OB) by the administration of varying concentrations of fluoride (F). Sodium fluoride (NaF) at concentrations of 0, 0.5, 5, 10, and 20mg/L was administered to cultured OB. The percentage of G(1)/G(0) (Gap 1/Gap 0), S (synthesis), G(2)/M (Gap 2/M, mitosis), and apoptosis rates in OB were analyzed with a Fluorescence-activated Cell Sorter (FACS) by propidium iodine (PI) staining after F treatment of 72 h. Effects of F treatment on COL1A1 and COL1A2 mRNA and collagen I protein levels were determined using quantitative real time RT-PCR (qRT-PCR) and immunofluorescence, respectively. This study demonstrates that there is a pronounced negative effect of long term NaF treatment on OB survival. These negative effects include an inhibition of the transformation from S phase into G(2)/M phase, increased apoptosis, and decreased COL1A1 mRNA, down-regulating the synthesis of COL I protein. The results suggest that COL I protein degradation in OB from F toxicity is due to a depletion of COL1A1 mRNA and not COL1A2.
The Prostate | 2012
Eddie Yeung; Alex Morrison; Daniel Plumeri; Jingying Wang; Chao Tong; Xiaoyan Yan; Ji Li
Alternol is an original compound purified from the fermentation products of Alternaria alternata var. monosporus, a microorganism from the bark of the yew tree. It has been reported that Alternol can inhibit proliferation of mouse leukemia cells and human gastric carcinoma cells, the aim of this study was to investigate the effects of Alternol on prostate cancer cells in comparison to prostate cells.
Journal of Diabetes | 2010
Chao Tong; Alex Morrison; Xiaoyan Yan; Peng Zhao; Eddie Yeung; Jingying Wang; Jianxin Xie; Ji Li
Background: It has become evident that macrophage migration inhibitory factor (MIF) is associated with the development of Type 1 diabetes mellitus. The aim of the present study was to determine whether MIF plays a role in cardiac contractile dysfunction in T1DM mice.
Circulation | 2013
Jingying Wang; Chao Tong; Xiaoyan Yan; Eddie Yeung; Sunilkumar Gandavadi; Alissa A. Hare; Xin Du; Yibang Chen; Huabao Xiaong; Lin Leng; Changxing Ma; Lawrence H. Young; William L. Jorgensen; Ji Li; Richard Bucala
Background Macrophage migration inhibitory factor (MIF) exerts a protective effect on ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules that increase the affinity of MIF for its receptor have been recently designed, and we hypothesized that such agonists may enhance AMPK activation and limit ischemic tissue injury.Background— Macrophage migration inhibitory factor (MIF) exerts a protective effect on ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules that increase the affinity of MIF for its receptor have been recently designed, and we hypothesized that such agonists may enhance AMPK activation and limit ischemic tissue injury. Methods and Results— Treatment of cardiomyocytes with the candidate MIF agonist, MIF20, augmented AMPK phosphorylation, increased by 50% the surface localization of glucose transporter, and enhanced by 25% cellular glucose uptake in comparison with MIF alone. In mouse hearts perfused with MIF20 before no-flow ischemia and reperfusion, postischemic left ventricular function improved commensurately with an increase in cardiac MIF-AMPK activation and an augmentation in myocardial glucose uptake. By contrast, small-molecule MIF agonism was not effective in cells or tissues genetically deficient in MIF or the MIF receptor, verifying the specificity of MIF20 for MIF-dependent AMPK signaling. The protective effect of MIF20 also was evident in an in vivo regional ischemia model. Mice treated with MIF20 followed by left coronary artery occlusion and reperfusion showed a significant reduction in infarcted myocardium. Conclusions— These data support the pharmacological utility of small-molecule MIF agonists in enhancing AMPK activation and reducing cardiac ischemic injury.
Circulation | 2013
Jingying Wang; Chao Tong; Xiaoyan Yan; Eddie Yeung; Sunilkumar Gandavadi; Alissa A. Hare; Xin Du; Yibang Chen; Huabao Xiong; Changxing Ma; Lin Leng; Lawrence H. Young; William L. Jorgensen; Ji Li; Richard Bucala
Background Macrophage migration inhibitory factor (MIF) exerts a protective effect on ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules that increase the affinity of MIF for its receptor have been recently designed, and we hypothesized that such agonists may enhance AMPK activation and limit ischemic tissue injury.Background— Macrophage migration inhibitory factor (MIF) exerts a protective effect on ischemic myocardium by activating AMP-activated protein kinase (AMPK). Small molecules that increase the affinity of MIF for its receptor have been recently designed, and we hypothesized that such agonists may enhance AMPK activation and limit ischemic tissue injury. Methods and Results— Treatment of cardiomyocytes with the candidate MIF agonist, MIF20, augmented AMPK phosphorylation, increased by 50% the surface localization of glucose transporter, and enhanced by 25% cellular glucose uptake in comparison with MIF alone. In mouse hearts perfused with MIF20 before no-flow ischemia and reperfusion, postischemic left ventricular function improved commensurately with an increase in cardiac MIF-AMPK activation and an augmentation in myocardial glucose uptake. By contrast, small-molecule MIF agonism was not effective in cells or tissues genetically deficient in MIF or the MIF receptor, verifying the specificity of MIF20 for MIF-dependent AMPK signaling. The protective effect of MIF20 also was evident in an in vivo regional ischemia model. Mice treated with MIF20 followed by left coronary artery occlusion and reperfusion showed a significant reduction in infarcted myocardium. Conclusions— These data support the pharmacological utility of small-molecule MIF agonists in enhancing AMPK activation and reducing cardiac ischemic injury.
Archive | 2011
Alex Morrison; Xiaoyan Yan; Chao Tong; Ji Li
Circulation | 2011
Jingying Wang; Xiaoyan Yan; Qiang Fu; Mingxia Cui; Likui Yang; Alireza R. Rezaie; Ji Li
Circulation | 2011
Jingying Wang; Xiaoyan Yan; Likui Yang; Alireza R. Rezaie; Ji Li